Acquired Resistance of EGFR-Mutated Lung Cancer to Tyrosine Kinase Inhibitor Treatment Promotes PARP Inhibitor Sensitivity

Lung cancers with oncogenic mutations in the epidermal growth factor receptor (EGFR) invariably acquire resistance to tyrosine kinase inhibitor (TKI) treatment. Vulnerabilities of EGFR TKI-resistant cancer cells that could be therapeutically exploited are incompletely understood. Here, we describe a...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Cell Rep
Hlavní autoři: Marcar, Lynnette, Bardhan, Kankana, Gheorghiu, Liliana, Dinkelborg, Patrick, Pfäffle, Heike, Liu, Qi, Wang, Meng, Piotrowska, Zofia, Sequist, Lecia V., Borgmann, Kerstin, Settleman, Jeffrey E., Engelman, Jeffrey A., Hata, Aaron N., Willers, Henning
Médium: Artigo
Jazyk:Inglês
Vydáno: 2019
Témata:
Article
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC6624074/
https://ncbi.nlm.nih.gov/pubmed/31216465
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.celrep.2019.05.058
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky